

Special Issue

Antibiotic Therapies for Multidrug-Resistant Infections

Message from the Guest Editor

The rapid emergence and global spread of multidrug-resistant (MDR) pathogens represent one of the most urgent threats to public health. Traditional antibiotics are increasingly failing against critical-priority bacteria, and the development of new therapeutic options has not kept pace with the rise in resistance. This Special Issue of *Antibiotics* (IF 4.6) aims to gather high-quality original research articles, reviews, and clinical case reports addressing innovative strategies to combat MDR infections. Topics of interest include, but are not limited to, novel antimicrobial agents, optimized antibiotic combinations, pharmacokinetic and pharmacodynamic advances, alternative and adjunctive therapies, antimicrobial stewardship interventions, and translational research bridging bench to bedside. By bringing together cutting-edge findings from basic science, clinical trials, and real-world practice, we hope to foster a deeper understanding of effective MDR management and inspire new approaches to preserve the efficacy of our antimicrobial arsenal. We invite contributions from researchers and clinicians worldwide to advance the fight against these challenging infections.

Guest Editor

Dr. Antonio Riccardo Buonomo

Division of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy

Deadline for manuscript submissions

31 January 2027



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/252087

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)